TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02303444

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients can get sorafenib at any time during study.

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients can get sorafenib at any time during study.

Intervention type: DRUG
Intervention: Other Multikinase inhibitors
Description: Patients can get MKIs at any time during study.

Intervention type: DRUG
Intervention: Other Multikinase inhibitors
Description: Patients can get MKIs at any time during study.
Study: NCT00680537

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercises
Description: Completion of a series of shoulder exercises for 6 weeks post device implant
Study: NCT01549496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: amlodipine 2.5 mg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: diltiazem 120 mg qd
Study: NCT01585038

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: 600mg orally every evening

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilpivirine
Description: 25mg orally once daily
Study: NCT03148990

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles and Rubella vaccine
Description: Administration of the experimental vaccine (MR).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles, Mumps and Rubella vaccine
Description: Administration of the comparator vaccine (MMR).
Study: NCT02563704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quinine
Study: NCT01040741

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study

Intervention type: OTHER
Intervention: Non-intervention observational study
Description: Non-intervention observational study
Study: NCT00877422

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
Study: NCT01145885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: PLK-1 inhibitor
Study: NCT04767035

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam / ketamine sublingual tablet
Description: sublingual tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam / ketamine sublingual tablet
Description: sublingual tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam / ketamine sublingual tablet
Description: sublingual tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam / ketamine sublingual tablet
Description: sublingual tablet
Study: NCT01191086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: USL255
Study: NCT05719818

Intervention type: DRUG
Intervention: biphosphonates
Description: Initiation of bisphosphonate therapy

Intervention type: PROCEDURE
Intervention: Dental care
Description: Surgical dental care
Study: NCT03329391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nurse-led cognitive-behavioral-based group intervention
Description: The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.
Study: NCT00771849

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate
Description: 0.5 mL, Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus Influenzae Type b (Hib) vaccine
Description: 0.5 mL, Intramuscular
Study: NCT03748433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Commercially available Dexcom G6 Continuous Glucose Monitoring

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dexcom G6 CGM
Description: Commercially available Dexcom G6 Continuous Glucose Monitoring
Study: NCT03293277

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Dexmedetomidine
Description: Intranasal Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Intravenous Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Intravenous Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Intravenous Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Dexmedetomidine
Description: Intravenous Dexmedetomidine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Placebo
Description: Intranasal Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Intravenous Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Intravenous Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Intravenous Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Placebo
Description: Intravenous Placebo
Study: NCT00964548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: 1.25 mg/kg IV once over 60 min

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dantrolene
Description: 2.5 mg/kg IV once over 60 min
Study: NCT03477526

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation program
Description: 3 weeks, ...

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation program
Description: 3 weeks, ...
Study: NCT03650348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-343 in Combination with Atezolizumab
Description: HER2/4-1BB Bispecific
Study: NCT02259036

Intervention type: OTHER
Group type: OTHER
Intervention: Ecological Momentary Treatment Enhancement
Description: Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
Study: NCT04263142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Tablet
Description: GSK3640254 tablets will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Capsule
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3640254 Capsule
Description: GSK3640254 capsules will contain mesylate salt with a unit dose of 100 mg (2x100 mg) and will be administered orally.
Study: NCT03748433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tandem t:slim X2 Insulin Pump
Description: sensor augmented insulin pump with predictive low glucose suspend
Study: NCT03184558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemcentinib; pembrolizumab
Description: Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.
Study: NCT00893373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: Standard AML chemotherapy plus sorafenib 400 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Standard AML chemotherapy plus placebo
Study: NCT00127829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral tablet
Study: NCT02009358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mental health promotion
Study: NCT02319785

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAT-NMES
Description: This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RAT-MT
Description: This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mirror therapy
Description: This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unilateral RAT
Description: This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral RAT
Description: This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.~The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
Study: NCT02136303

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: S3: Kale extract: AMD-patients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: S3: Kale extract: AMD-patients
Study: NCT01546142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deoxycholic acid injection
Description: Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate buffered saline placebo for injection
Study: NCT01398059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary
Description: In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary With Breaks
Description: In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
Study: NCT00238394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cediranib maleate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04337047

Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment

Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment

Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment
Study: NCT01398059

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sedentary With Breaks and Physical Activity
Description: In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
Study: NCT04337047

Intervention type: OTHER
Intervention: questionnaire assesment
Description: questionnaire assesment
Study: NCT03670732

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: continuous positive airway pressure
Description: Continuous positive airway pressure is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal intermittent positive pressure ventilation
Description: NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal intermittent positive pressure ventilation
Description: NIPPV is applied for 12 hours at a mean airway pressure that is the same as the subject was receiving prior to entry into the study
Study: NCT01869426

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3 drops

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: VSL#3 drops placebo
Study: NCT03836482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Selective Cytopheretic Device
Description: Treatment will be delivered for 6 hours a day for up to 6 consecutive days.
Study: NCT01463033

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levetiracetam
Description: 55 mg/kg/day given in 2 divided doses 12 hours apart
Study: NCT01348191

Intervention type: PROCEDURE
Intervention: Myometrial biopsy
Description: At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
Study: NCT02957539

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial rewards
Description: Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Financial rewards
Description: Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
Study: NCT02905968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transanual tube placement
Description: Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
Study: NCT03889678

Intervention type: DIAGNOSTIC_TEST
Intervention: Color flow doppler
Description: Color flow doppler proximal to vein insertion site to document flow
Study: NCT00596167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous antibiotics
Description: Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
Study: NCT02773160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sensor-based postural feedback
Description: Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror feedback
Description: Subjects will receive feedback from a mirror during the learning phase of a motor control task

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Subjects will receive no feedback during the learning phase of a motor control task
Study: NCT03683628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PB-MNC therapy
Description: The patients will receive subcutaneous injection of Granulocyte colony stimulating factor (G-CSF) for 3 day. The mononuclear cell will be collected by blood cell separator. The 120 cc of cell solution will be injected into calf or thigh of ischemic limb (1cc per site) with needle no. 25 gauge. Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: No PB-MNC therapy
Description: Patients will receive ASA 81 mg once daily and walking exercise 3 times/ week
Study: NCT01377519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MR Guided Focused Ultrasound
Description: This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo MR Guided Focused Ultrasound
Description: This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
Study: NCT02618317

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Lock Solution
Description: Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trissodium Citrate 30%
Description: ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline-EDTA 30 mg/ml - 3 mg/ml
Description: ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
Study: NCT01455051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
Study: NCT04213560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: weighted waist-hooping
Description: weighted waist-hooping
Study: NCT03275077

Intervention type: DEVICE
Intervention: Thromboelastography
Description: A viscoelastic test of coagulation

Intervention type: DEVICE
Intervention: Thromboelastography
Description: A viscoelastic test of coagulation
Study: NCT01738802

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Anti-oxidant and micronutrient
Description: This group will be randomized to take the anti-oxidant and micronutrient supplement.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This group will take a placebo.